PaloBiofarma
A company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
CAD42—63m (Dealroom.co estimates Feb 2024.)
Company register number B63998843
Mataró Catalonia (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 20.0m | 10.0m | <1m | 10.0m | <1m |
| % growth | - | (50 %) | (94 %) | 1567 % | (93 %) |
| EBITDA | 20.0m | 10.0m | (1.0m) | 10.0m | (<1m) |
| % EBITDA margin | 100 % | 100 % | (167 %) | 100 % | (114 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€2.0m | Seed | ||
* | €1.0m | Seed | |
€330k | Grant | ||
* | €4.5m | Early VC | |
€2.5m | Grant | ||
N/A | Early VC | ||
* | N/A | Convertible | |
* | N/A | Grant | |
* | €7.0m | Early VC | |
| Total Funding | CAD26.0m | ||
Related Content
Recent News about PaloBiofarma
EditMore about PaloBiofarma
EditDeveloper of drugs intended to cure diseases based on the modulation of adenosine receptors. The company focuses to discover the first marketed drug based on a selective adenosine receptor modulator leveraging medicinal chemistry and in vitro pharmacology of adenosine, enabling doctors to focus on the treatment of advanced prostate cancer.
Keywords: Pharmaceuticals and Biotechnology, Adenosine Pharmaceutical, Adenosine Receptor, Cancer Therapy, Cancer Treatment, Clinical Development, Medical Services.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.